Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.

Item

http://www.wikidata.org/entity/Q38578404

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.

@en

type

Item

label

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.

@en

prefLabel

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.

@en

P1476

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.

@en

P2093

Armando Perrella

http://www.w3.org/2001/XMLSchema#string

Franco Roviello

http://www.w3.org/2001/XMLSchema#string

Giandomenico Roviello

http://www.w3.org/2001/XMLSchema#string

Roberto Petrioli

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Global cancer statistics, 2012

The biology of VEGF and its receptors

Comprehensive molecular characterization of gastric adenocarcinoma

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Basic and therapeutic aspects of angiogenesis

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

P2888

s10120-015-0537-5

P304

31-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-015-0537-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Karol Polom

Luigi Marano

Daniele Marrelli

P577

2015-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024456233

http://www.w3.org/2001/XMLSchema#string

P698

26329368

http://www.w3.org/2001/XMLSchema#string